Get the Stockscreener App
40.66
3.88%
1.52
Kymera Therapeutics Inc Stock (KYMR) Forecast
The Kymera Therapeutics Inc (KYMR) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $38.61, representing a -5.05% decrease from the current price of $40.66. The highest analyst price target is $44.28, and the lowest is $32.93.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month KYMR Price Target
Average 52.55
(+29.24% Upside)
Is Kymera Therapeutics Inc (KYMR) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 40.14 | Neutral |
| STOCH(9,6) | 22.16 | Neutral |
| STOCHRSI(14) | 33.89 | Neutral |
| MACD(12,26) | -1.6085 | Sell |
| ADX(14) | 16.22 | Neutral |
| William %R | -66.53 | Neutral |
| CCI(14) | -107.73 | Sell |
Buy: 0
Sell: 2
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
42.22
Sell
|
41.95
Sell
|
| MA20 |
44.27
Sell
|
43.40
Sell
|
| MA50 |
45.95
Sell
|
44.88
Sell
|
| MA100 |
45.85
Sell
|
44.29
Sell
|
| MA200 |
41.32
Sell
|
40.20
Buy
|
Buy: 1
Sell: 9
Neutral: 0
Summary: Sell
According to our latest analysis, KYMR could be considered a Strong Sell, with 17 technical analysis indicators signaling 1 Buy signals, 11 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on KYMR, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 40.14 indicates that KYMR is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 22.16 indicates that KYMR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 33.89 indicates that KYMR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 16.22 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -107.73 indicates that KYMR is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term KYMR price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Kymera Therapeutics Inc financial reports and earnings history, Kymera Therapeutics Inc (KYMR) stock could reach $72.56 by 2030, $43.61 by 2040 and $102.77 by 2050. See the projected annual prices until 2050 of the Kymera Therapeutics Inc stock below:
- Kymera Therapeutics Inc (KYMR) is expected to reach an average price of $31.01 in 2035, with a high prediction of $41.92 and a low estimate of $30.49. This indicates an $-23.73% rise from the last recorded price of $40.66.
- Kymera Therapeutics Inc (KYMR) stock is projected to chart a bullish course in 2040, with an average price target of $39.67, representing an $-2.43% surge from its current level. The forecast ranges from a conservative $38.62 to a sky-high $43.61.
- Our analysts predict Kymera Therapeutics Inc (KYMR) to jump 34.41% by 2045, soaring from $45.76 to an average price of $54.65, potentially reaching $54.89. While $45.76 is the low estimate, the potential upside is significant.
- Kymera Therapeutics Inc (KYMR) stock is expected to climb by 2050, reaching an average of $75.64, a $86.02% jump from its current level. However, a wide range of estimates exists, with high and low targets of $102.77 and $74.02, respectively, highlighting the market's uncertainty.
Kymera Therapeutics Inc Stock (KYMR) Year by Year Forecast
Kymera Therapeutics Inc Stock (KYMR) Price Forecast for 2025
Kymera Therapeutics Inc Stock (KYMR) is expected to reach an average price of $52.55 in 2025, with a high prediction of $72.16 and a low estimate of $32.93. This indicates an +29.24% rise from the last recorded price of $40.66.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $41.05 | $32.93 | $44.28 | +0.95% |
| February, 2025 | $47.75 | $40.66 | $53.48 | +17.44% |
| March, 2025 | $50.37 | $45.40 | $55.95 | +23.87% |
| April, 2025 | $53.23 | $45.36 | $61.17 | +30.92% |
| May, 2025 | $56.97 | $52.62 | $66.46 | +40.10% |
| June, 2025 | $63.07 | $51.36 | $67.14 | +55.12% |
| July, 2025 | $63.27 | $59.14 | $70.62 | +55.60% |
| August, 2025 | $61.80 | $55.30 | $65.43 | +52.00% |
| September, 2025 | $56.84 | $55.44 | $72.16 | +39.78% |
| October, 2025 | $64.82 | $51.81 | $65.57 | +59.43% |
| November, 2025 | $41.10 | $40.75 | $69.50 | +1.08% |
| December, 2025 | $41.86 | $38.50 | $49.28 | +2.96% |
Kymera Therapeutics Inc Stock (KYMR) Price Forecast for 2026
The predicted value for Kymera Therapeutics Inc (KYMR) in 2026 is set at an average of $32.03. Estimates vary from a peak of $47.82 to a trough of $16.24, indicating an -21.23% surge from the present price of $40.66.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $41.50 | $37.35 | $44.66 | +2.06% |
| February, 2026 | $44.73 | $37.58 | $47.82 | +10.02% |
| March, 2026 | $34.43 | $32.89 | $46.74 | -15.33% |
| April, 2026 | $17.35 | $16.70 | $35.84 | -57.32% |
| May, 2026 | $23.22 | $16.24 | $23.33 | -42.90% |
| June, 2026 | $26.32 | $22.07 | $29.54 | -35.26% |
| July, 2026 | $35.10 | $23.43 | $38.13 | -13.68% |
| August, 2026 | $32.45 | $28.78 | $38.29 | -20.18% |
| September, 2026 | $25.11 | $21.95 | $32.68 | -38.24% |
| October, 2026 | $33.98 | $24.94 | $35.67 | -16.44% |
| November, 2026 | $32.10 | $29.74 | $36.06 | -21.05% |
| December, 2026 | $28.09 | $27.16 | $37.36 | -30.92% |
Kymera Therapeutics Inc Stock (KYMR) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Kymera Therapeutics Inc (KYMR) is $27.88, with a high forecast of $42.98 and a low forecast of $12.79. This indicates an -31.42% decrease from the last price of $40.66.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $39.98 | $27.31 | $40.88 | -1.67% |
| February, 2027 | $36.81 | $35.02 | $42.98 | -9.48% |
| March, 2027 | $34.18 | $31.67 | $37.93 | -15.93% |
| April, 2027 | $36.01 | $31.09 | $37.73 | -11.45% |
| May, 2027 | $31.50 | $29.15 | $38.60 | -22.53% |
| June, 2027 | $25.88 | $25.88 | $34.15 | -36.36% |
| July, 2027 | $25.64 | $25.05 | $31.76 | -36.94% |
| August, 2027 | $25.05 | $24.31 | $26.55 | -38.40% |
| September, 2027 | $22.25 | $21.70 | $28.36 | -45.27% |
| October, 2027 | $20.68 | $20.13 | $23.23 | -49.15% |
| November, 2027 | $15.33 | $14.55 | $20.51 | -62.29% |
| December, 2027 | $22.62 | $12.79 | $23.08 | -44.37% |
Kymera Therapeutics Inc Stock (KYMR) Price Forecast for 2028
In 2028, Kymera Therapeutics Inc (KYMR) is projected to reach an average price of $59.99, with a high projection of $97.89 and a low estimate of $22.08. This indicates an +47.53% rise from the last price of $40.66.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $26.19 | $22.08 | $28.38 | -35.58% |
| February, 2028 | $30.38 | $24.39 | $33.13 | -25.29% |
| March, 2028 | $36.17 | $28.22 | $37.70 | -11.03% |
| April, 2028 | $45.91 | $35.04 | $48.52 | +12.91% |
| May, 2028 | $43.41 | $41.96 | $48.19 | +6.78% |
| June, 2028 | $36.59 | $35.97 | $43.77 | -10.01% |
| July, 2028 | $37.82 | $32.83 | $41.05 | -6.98% |
| August, 2028 | $38.24 | $31.36 | $38.93 | -5.94% |
| September, 2028 | $43.44 | $33.59 | $47.65 | +6.85% |
| October, 2028 | $55.81 | $40.45 | $59.44 | +37.27% |
| November, 2028 | $77.48 | $50.72 | $81.21 | +90.55% |
| December, 2028 | $83.49 | $65.42 | $97.89 | +105.33% |
Kymera Therapeutics Inc Stock (KYMR) Price Forecast for 2029
The 2029 price forecast for Kymera Therapeutics Inc Stock (KYMR) is $64.70 on average, with a high prediction of $93.46 and a low estimate of $35.93. This represents an +59.12% increase from the previous price of $40.66.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $60.67 | $59.05 | $93.46 | +49.21% |
| February, 2029 | $50.66 | $46.62 | $66.85 | +24.59% |
| March, 2029 | $39.45 | $38.89 | $54.03 | -2.98% |
| April, 2029 | $50.07 | $35.93 | $54.21 | +23.13% |
| May, 2029 | $56.58 | $44.06 | $58.97 | +39.15% |
| June, 2029 | $62.47 | $48.38 | $63.40 | +53.63% |
| July, 2029 | $66.23 | $52.28 | $66.90 | +62.88% |
| August, 2029 | $68.20 | $54.39 | $70.17 | +67.73% |
| September, 2029 | $68.57 | $64.26 | $73.65 | +68.64% |
| October, 2029 | $61.76 | $58.34 | $71.16 | +51.90% |
| November, 2029 | $67.59 | $60.09 | $75.21 | +66.23% |
| December, 2029 | $59.15 | $57.30 | $69.14 | +45.48% |
Kymera Therapeutics Inc Stock (KYMR) Price Forecast for 2030
Kymera Therapeutics Inc Stock (KYMR) is expected to reach an average price of $45.94 in 2030, with a high forecast of $72.56 and a low forecast of $19.32. This signifies an +12.99% surge from the last price of $40.66.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $47.18 | $45.89 | $72.56 | +16.04% |
| February, 2030 | $45.85 | $41.56 | $51.11 | +12.77% |
| March, 2030 | $45.89 | $41.17 | $52.34 | +12.87% |
| April, 2030 | $46.57 | $40.42 | $49.72 | +14.54% |
| May, 2030 | $40.03 | $39.77 | $50.89 | -1.54% |
| June, 2030 | $20.95 | $19.80 | $41.09 | -48.47% |
| July, 2030 | $21.94 | $19.32 | $23.80 | -46.03% |
| August, 2030 | $32.54 | $22.29 | $32.63 | -19.96% |
| September, 2030 | $37.36 | $26.52 | $37.44 | -8.11% |
| October, 2030 | $33.66 | $31.88 | $41.39 | -17.23% |
| November, 2030 | $27.99 | $27.03 | $36.09 | -31.17% |
| December, 2030 | $36.22 | $25.06 | $36.48 | -10.93% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):